Increasing cancer permeability by photodynamic priming: from microenvironment to mechanotransduction signaling

Nazareth Milagros Carigga Gutierrez1, Núria Pujol-Solé1, Qendresa Arifi1

  • 1Université Grenoble Alpes, Inserm U 1209, CNRS UMR 5309, Institute for Advanced Biosciences, 38000, Grenoble, France.

Cancer Metastasis Reviews
|September 26, 2022
PubMed

Insights

Photodynamic therapy (PDT) enhances cancer treatment by increasing drug penetration without promoting metastasis. This "photodynamic priming" improves drug delivery and efficacy by altering the tumor microenvironment.

Area of Science:

  • Oncology
  • Biomedical Engineering
  • Cancer Therapeutics

Background:

  • The dense tumor microenvironment impedes anticancer drug delivery, limiting treatment efficacy.
  • Previous strategies to enhance drug penetration showed limited success and increased toxicity.
  • Photodynamic therapy (PDT) offers a novel approach to overcome these limitations.

Purpose of the Study:

  • To review the mechanisms by which PDT enhances cancer tissue permeability.
  • To elucidate how PDT-induced "photodynamic priming" improves drug delivery without promoting metastasis.
  • To identify knowledge gaps in PDT's application as an adjuvant cancer therapy.

Main Methods:

  • Review of existing literature on PDT and cancer microenvironment interactions.
  • Analysis of PDT's effects on extracellular matrix proteins and cancer cell adhesion.
  • Investigation of PDT's impact on mechanotransduction pathways involved in cancer cell migration.

Main Results:

  • PDT increases cancer tissue permeability by degrading extracellular matrix proteins.
  • PDT reduces cancer cell adhesion to the altered matrix, without promoting migration.
  • PDT interferes with signaling pathways that drive cancer cell migration and differentiation.

Conclusions:

  • Photodynamic priming is a promising strategy to improve drug delivery and efficacy in cancer treatment.
  • PDT enhances cancer permeability without increasing metastatic potential.
  • Further research is needed to optimize PDT dosimetry and understand underlying signaling pathways for clinical translation.

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.4K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.7K